 |
|||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||||||||||||||||
|
 |
|
|
|
|
|||||||||||||||||||||||||||||||||||||
|
IsoAmp® Factor V Leiden SNP Detection |
|||||||||||||||||||||||||||||||||||||||||
 |
||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||
| Description:
|
||||||||||||||||||||||||||||||||||||||||||
| Factor V Leiden
is the most common hereditary blood coagulation disorder in the United
States. It affects about 5% of the Caucasian population. The disease
is less common in Hispanics and African-Americans. The cause of this disorder is a single nucleotide change (G to A at position 1691) of the Factor V gene, referred to as the Factor V Leiden mutation, resulting in a change in the protein sequence from an arginine to a glutamine at position 506. The mutant protein cannot be inactivated by activated protein C, which eventually leads to excess fibrin and clotting. A 121 bp target fragment is amplified by isothermal Helicase Dependent Amplification (HDA) using one common primer and two allele specific primers: one for the wild type G (labeled with FI) and the other for the mutant A (labeled with DIG). After amplification, the reaction tube is placed in a Type II BESt™ cassette for genotype determination. A Wild-type allele (W) will show a visible T line and Mutant allele (M) will show a colored C line (Figure 1). Both T and C lines will be visible for a heterozygous genotype (H). It is invalid if no visible line is observed. |
||||||||||||||||||||||||||||||||||||||||||
Advantages: "Instrument
free" genotypingRapid turnaround
time (< 2 hours)Easy-to-read
test results
|
||||||||||||||||||||||||||||||||||||||||||
| For additional information, please contact us. | ||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||
|
||
| Privacy, Limitation, Warranty, Disclaimer | ||
|
||